T8388

Vonoprazan (TAK-438 (free base)) is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis

4-(3,4-Difluorobenzo)curcumin (CDF) is a semisynthetic coumarin noted for its antiparasitic and anticancer properties. It effectively reduces the population of Vero cells infected by T. gondii promastigotes and amastigotes, with EC50 values of 0.8 and 0.37 µM, respectively. Furthermore, at concentrations of 4 and 8 µM, CDF enhances the efficacy of 5-fluorouracil and oxaliplatin in inhibiting the formation of both primary and secondary colonospheres in chemoresistant HCT116 cells.

XY-4, a derivative of 1-palmitoyl lysophosphatidic acid (1-palmitoyl LPA094) and an agonist of peroxisome proliferator-activated receptor γ (PPARγ), effectively induces reporter gene expression in RAW 264.7 macrophages harboring a peroxisome proliferator-response element (PPRE) at a concentration of 5 µM. Unlike its action on PPARγ, XY-4 does not serve as an agonist for lysophosphatidic acid receptor 1 (LPA1), LPA2, or LPA3. Furthermore, at a lower concentration of 1 µM, it promotes platelet aggregation in vitro and triggers carotid artery neointima formation in rats.